Baidu
map

Ophthalmic Plast Reconstr Surg:眼睑软组织软骨瘤病例首次报告

2018-08-21 cuiguizhong MedSci原创

美国北卡罗来纳州温斯顿-塞勒姆维克森林医学院病理学系眼科的Aseem F和Pace ST等近日在Ophthalmic Plast Reconstr Surg杂志上发表了一篇重要的文章,他们报告了首例眼睑软组织软骨瘤的病例。

美国北卡罗来纳州温斯顿-塞勒姆维克森林医学院病理学系眼科的Aseem F和Pace ST等近日在Ophthalmic Plast Reconstr Surg杂志上发表了一篇重要的文章,他们报告了首例眼睑软组织软骨瘤的病例。

一名54岁的女性患者,中央右下眼睑患有缓慢生长的皮下结节,位于泪小管下端附近,患病有2年左右的时间。在检查时,患者报告说有右侧溢泪,这暗示泪道可能出现流出阻塞。 进行手术切除的结节与软骨瘤一致。这是一种罕见的肿瘤,软组织软骨瘤,最常见于四肢,但也见于头颈部。

据他们所知,这是第一例报告眼睑软组织软骨瘤的病例。

原文出处:

Aseem, F., et al., Soft Tissue Chondroma of the Eyelid. Ophthalmic Plast Reconstr Surg, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2019-01-27 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-12-05 drj2003
  4. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-22 131****1460

    学习了受益匪浅

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1684107, encodeId=cfd3168410ed9, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sat Nov 03 18:06:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711594, encodeId=4fe41e1159436, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 27 02:06:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977565, encodeId=254719e7565f5, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Dec 05 07:06:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420416, encodeId=1ac91420416a1, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541373, encodeId=e8d515413e36d, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630654, encodeId=5f271630654ee, content=<a href='/topic/show?id=40529355e79' target=_blank style='color:#2F92EE;'>#软骨瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93557, encryptionId=40529355e79, topicName=软骨瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e0521549607, createdName=flyingeagle84, createdTime=Thu Aug 23 13:06:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340103, encodeId=7842340103d6, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Aug 22 08:15:49 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340010, encodeId=5f5b34001031, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Aug 21 23:07:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

相关资讯

盘点:眼科全新综述

J Neuroophthalmol:综述-眼睛疼痛和偏头痛 犹他大学莫兰眼科中心的眼科和神经科的Digre KB近日在J Neuroophthalmol发表了一篇综述,系统性的总结了眼睛疼痛和偏头痛的相似性,并对其引起的症状进行了讨论。 长期以来,偏头痛一直被认为与视力障碍有关,尤其是伴有先兆的偏头痛。然而,眼睛在感官处理中也起着重要的作用。他们发现偏头痛患者的视觉生活质量下降。在这篇

Ophthalmol Ther : 快速帮助眼科医生确定对患有“磺胺过敏”的患者的药物是否安全

美国亚利桑那大学医学院的Shah TJ和犹他大学医学院眼科与视觉科学系的Moshirfar M近日在Ophthalmol Ther发表了一篇有趣的文章,他们针对眼保健专家,提出一种以证据为基础的方法,澄清某些药物是否应该用于磺胺类过敏患者。

盘点:近期眼科病例报告及调查研究

Optom Vis Sci:体外受精后出现眼部肌无力症状的病例报告 韩国江原大学医院眼科的Yoo YJ近日在Optom Vis Sci发表一项他们实验室的工作,他们报告了一例女性患者,在体外受精后第一天,出现的血清反应呈阴性的眼肌无力的病例。 眼肌无力症是重症肌无力的局部表现形式,它是一种神经肌肉接头的突触后障碍,主要是由自身免疫机制引起的眼外肌群收缩减弱。在患有重症肌无力的女性中,性

陆方:最见不得孩子失明,我几乎是用跑的奔进手术室

一个人所学的专业可以是入门砖,也可能是未来发展的机遇。四川大学华西医院眼科副主任陆方是个善于抓住机遇,并能够把握好机遇的人。

盘点:眼科治疗新技术及眼科手术改进进展

1. 眼科治疗新技术应用 Nanomaterials (Basel):基于纸的微流体平台发现外泌体在引起失明的疾病中具有致病作用 台湾台中市中山医科大学附属医院眼科的Hsu MY最近在Nanomaterials (Basel)发表了一篇文章,他们通过对房水进行分析,发现在主要导致失明的威胁性疾病如年龄相关性黄斑变性、青光眼和角膜营养不良中,外泌体具有致病作用。 具体实验设计如下,他们

盘点:眼科潜在的治疗策略

1. 眼科潜在治疗策略 J Cell Mol Med:角膜缘细胞是成体间充质干细胞的有效来源 深圳大学眼视光学院深圳眼科医院的Guo P近日在J Cell Mol Med发表了一篇文章,他们论述了角膜缘细胞是成体间充质干细胞的有效来源。 角膜缘细胞是位于角膜缘基底上皮细胞旁边的间充质干细胞。角膜缘内环境细胞表达胚胎干细胞标志物,如Nanog、Nestin、Oct4、Rex1

Baidu
map
Baidu
map
Baidu
map